of patient-specific induced pluripotent stem cells (iPSCs) opens a new avenue for future applications of regenerative medicine. However, before iPSCs can be used in a clinical setting, it is critical to validate their in vivo fate following autologous transplantation. Thus far, preclinical studies have been limited to small animals, and have yet to be conducted in large animals that are physiologically more similar to humans. In this study, we report the first autologous transplantation of iPSCs in a large animal model through the generation of canine iPSCs (ciPSCs) from the canine adipose stromal cells (cASCs) and canine fibroblasts (cFibro) of adult Mongrel dogs. We confirmed pluripotency of ciPSCs using the following techniques: 1) immunostaining and quantitative PCR for the presence of pluripotent and germ layer specific markers in differentiated ciPSCs; 2) microarray analysis that demonstrates similar gene expression profiles between ciPSCs and canine embryonic stem cells (cESCs); 3) teratoma formation assays; and 4) karyotyping for genomic stability. Fate of ciPSCs autologously transplanted to the canine heart was tracked in vivo using clinical positron emission tomography (PET), computed tomography (CT), and magnetic resonance (MR) imaging. To demonstrate clinical potential of ciPSCs to treat models of injury, we generated endothelial cells (ciPSC-ECs) and used these cells to treat immunodeficient murine models of myocardial infarction and hindlimb ischemia.
Derivation
of patient-specific induced pluripotent stem cells (iPSCs) opens a new avenue for future applications of regenerative medicine. However, before iPSCs can be used in a clinical setting, it is critical to validate their in vivo fate following autologous transplantation. Thus far, preclinical studies have been limited to small animals, and have yet to be conducted in large animals that are physiologically more similar to humans. In this study, we report the first autologous transplantation of iPSCs in a large animal model through the generation of canine iPSCs (ciPSCs) from the canine adipose stromal cells (cASCs) and canine fibroblasts (cFibro) of adult Mongrel dogs. We confirmed pluripotency of ciPSCs using the following techniques: 1) immunostaining and quantitative PCR for the presence of pluripotent and germ layer specific markers in differentiated ciPSCs; 2) microarray analysis that demonstrates similar gene expression profiles between ciPSCs and canine embryonic stem cells (cESCs); 3) teratoma formation assays; and 4) karyotyping for genomic stability. Fate of ciPSCs autologously transplanted to the canine heart was tracked in vivo using clinical positron emission tomography (PET), computed tomography (CT), and magnetic resonance (MR) imaging. To demonstrate clinical potential of ciPSCs to treat models of injury, we generated endothelial cells (ciPSC-ECs) and used these cells to treat immunodeficient murine models of myocardial infarction and hindlimb ischemia.
In recent years, human embryonic stem cells (hESCs) have gained popularity as a potentially ideal cell candidate for regenerative medicine (1) . Clinical use of hESCs, however, remains challenging due to concerns about the use of human embryos and the risk of transplant rejection (2) . One way to circumvent these issues is to generate induced pluripotent stem cells (iPSCs) from adult somatic tissues (3) . iPSCs have been successfully generated from a variety of adult cell types through exogenous expression of various transcription factors (3, 4) . Numerous pre-clinical studies in small animals have demonstrated that adult cells can be successfully reprogrammed into iPSCs, differentiated into therapeutic cell types, and transplanted into damaged tissue for repair (5, 6) .
Despite promising results in small animal models, further evaluation is needed in large animal models, which are physiologically more similar to humans. Among large animals, the canine model is especially well suited for translational studies of iPSC-based therapies. Unlike the pig, canine embryonic stem cells (cESCs) have already been isolated and characterized and thus provide criteria for pluripotent canine cells (7) (8) (9) . Although both monkey ESCs and iPSCs have been previously derived, the use of primates remains controversial (7, 10) . In this study, we generated ciPSCs resembling cESCs from the somatic skin and fat of adult Mongrel dogs. We tested the efficacy of a canine model for pre-clinical optimization of iPSC delivery to the heart by monitoring stem cell fate using PET reporter gene imaging and iron oxide labeling by MR imaging.
Experimental Procedures
Adipose cell harvest and culture of ciPSCsAdipose tissue and skin were resected from three individual one-year old Mongrel dogs (Marshall Farms, CA) for digestion with collagenase II (Invitrogen, Carlsbad, CA) to a single cell solution for plating and culture in appropriate mediums. Derived ciPSCs were maintained on MEF feeder layers with ciPSC medium. Lentivirus production and transductionLentivirus for reprogramming transgenes or Fluc-RFP-HSVttk was collected from the supernatant of transfected 293FT cells and concentrated as previously described (11, 12) . Immunofluorescence and alkaline phosphatase staining-After cells were fixed, permeabilized, and blocked, incubation with primary and secondary antibody was performed. A list of the antibodies used in this study is included in Supplemental (12) . Clinical MR imaging-Imaging was performed on a Signa 3.0T Excite HD scanner (GE Healthcare Systems, Milwaukee, Wisconsin) and 8-element cardiac phased array coil. A T2 weighted GRE sequence was used to image ciPSCs incubated overnight with iron particles. Cine images of the left ventricle in short and long axes were acquired with a steady-state free precession sequence as previously described (13, 14) . Generation of canine endothelial cells (ciPSCECs) from ciPSCs-ciPSCs were differentiated into EBs in ultra-low attachment dishes using differentiation medium. After 16 days in culture, EBs were dissociated into single cells and placed in adherent cell culture conditions. Cells were lifted and FACs sorted for CD31. ciPSC-ECs were cultured using EBM-2 (Lonza, MD). Generation of myocardial infarction and intramyocardial delivery of ciPSC-ECs-8-10 week old SCID Beige mice (Charles Rivers, MA) were anesthetized by inhaled isoflurane (2% to 3%) and intubated and ventilated. A left thoracotomy was performed followed by ligation of the left anterior descending (LAD) artery for 30 minutes followed by reperfusion as previously described (15) . After 30 minutes, 1x10 6 ciPSC-ECs stably expressing Fluc-RFP-HSVttk were injected intramyocardially into 3 sites near the periinfarct zone at 20 ml of total volume (n=6).
Control animals received PBS injection instead (n= 6).
Optical bioluminescence (BLI) of cell survival and localization-To assess ciPSC-EC survival and engraftment in vivo, BLI was performed on animals receiving 375 mg/kg body weight dluciferin reporter probe. Living Image 4.0 (Caliper Life Sciences) was used to quantify signal intensity as previously described (15, 16) . Echocardiographic measurement of cardiac function-Animals receiving LAD artery ligation were scanned on days 0, 14, 28, and 42 using a Siemens-Acuson Sequoia C512 system equipped with a multifrequency (8-14 MHz) 15L8 transducer. Fractional shortening (FS) was acquired using standard M-mode image acquisitions of left ventricular short axis images as previously described (15, 16) . Hindlimb ischemia model-SCID Beige mice (Charles Rivers Laboratories, MA) were anesthetized with isoflurane (2-3%) after which unilateral hindlimb ischemia was induced by ligating the femoral artery as previously described (17) . To test the therapeutic potential of ciPSC-ECs, 1x10 6 cells stably expressing mRFP-Fluc were delivered by intra-muscular injection into the region of ischemia (n=5).
Control animals received PBS (n=5).
An expanded Methods section is provided in the Supplemental Methods section.
Results
Derivation of ciPSCs from adipose stromal cells and fibroblasts. We successfully reprogrammed canine adipose stromal cells (cASCs) and canine fibroblasts (cFibro) into ciPSCs from three individual dogs. We used lentivirus containing human Oct4, Sox2, Klf4, and c-MYC at a 1:1:1:1 ratio without chemical inhibitors. From days 12-15 post transduction, we observed clearly recognizable, tightly packed colonies with morphologic appearance similar to cESCs under bright field microscopy ( Figure  1A ). As previous studies characterizing cESCs have used TRA-1-60 as a marker of undifferentiation (7), we used TRA-1-60 in conjunction with typical ESC-like morphology to track the progression of the putative ciPSC colonies. In our reprogramming experiments, we consistently observed the appearance of TRA- Figure 1A , 1B, and Supplemental Figure 1 ). RT-PCR of these ciPSCs revealed expression of canine pluripotency genes Oct-4, Sox2, and Nanog at levels comparable to cESCs ( Figure 1C and Supplemental Figure 2 ). By comparison, cASCs isolated from canine tissue samples revealed very low or no expression of these genes.
Successful reprogramming of ciPSCs was further confirmed by whole genome expression profiling using microarray analysis comparing ciPSCs with cASCs and cESCs. ciPSCs showed a high degree of similarity in their gene expression profile with cESCs and importantly, were distinct from cASCs ( Figure  1D , Supplemental Figure 3 ). In addition, cFibro-derived ciPSCs were found to be similar to cASC-derived iPSCs and cESCs as well (Supplemental Figure 4) .
To test pluripotency of ciPSCs derived from cASCs and cFibro, we differentiated ciPSCs in vitro by embroid body (EB) formation. ciPSCs derived from both cASCs as Figure 2C, 2D ). ciPSCs were found to have a normal karyotype after extended culture for 30 passages with 78 chromosomes and no translocations, indicating genomic stability of clones over time ( Figure  2E) .
In vivo tracking of transplanted canine iPSCs using PET and MR imaging. To simulate use of ciPSCs for cell therapy, we next prepared c-ASC-iPSCs for autologous delivery into the same animals from which parental cells were isolated. To visualize anatomic localization and survival of cells after in vivo injection, ciPSCs were stably transduced with a lentivirus carrying a triple-fusion (TF) reporter gene consisting of firefly luciferase, red fluorescent protein, and herpes simplex truncated thymidine kinase (LV-Fluc-RFPHSVttk) driven by the ubiquitin promoter ( Figure 3A The minimum detectable cell concentration in the mouse was 1×10 6 cell/ml using microPET ( Figure 3D ). For the dog, the signal could be detected from the subcutaneous regions of the animal at a minimum concentration of 5×10 6 cells/ml using clinical PET/CT scanner. Specifically, the in vivo reporter gene expression for 5 and 10 million ciPSCs was 0.0004±0.0001 and 0.001±0.0003 percent injected dose per gram of tissue (%ID/g), respectively. As typical human trials for cellbased therapies can utilize billions of cells (18), PET-based reporter gene imaging modalities at a detection level of 5 million cells appears sensitive enough to enable accurate tracking of ciPSC delivery in vivo.
We next tested whether ciPSCs expressing the HSVttk reporter gene could be imaged at an anatomical site where signal attenuation due to tissue thickness is problematic (e.g., myocardium). Due to the therapeutic potential of iPSC therapy for cardiovascular disease and challenge of imaging cell delivery to the heart, we chose the left ventricular myocardial wall as a target. To confirm PET signals in our cardiac model as specific, we labeled ciPSCs with iron oxide particles for co-localization with MR imaging. Figure 4B ). After imaging, canine hearts were explanted immediately after in vivo imaging and cut into 100 mm sections. The location of the cells in the myocardium was further confirmed by ex vivo micro PET imaging ( Figure 4C ) and histological analysis (Supplemental Figure 7) .
Generation of endothelial cells from ciPSCs and transplantation into murine hindlimb ischemia model-As undifferentiated iPSCs are not a cell type directly amenable for clinical transplantation, we sought to demonstrate therapeutic applications of these cells through differentiation of ciPSCs into endothelial cells (ciPSC-ECs). Like human and murine ESC-ECs and iPSC-ECs generated in previous studies (15) (16) (17) 19, 20) , ciPSC-ECs were positive for CD31, capable of DiI-ac-LDL uptake, and formed tubules when cultured on Matrigel in vitro (Supplemental Figure 8A ). To assess in vivo therapeutic potential of ciPSCECs, we stably transduced ciPSC-ECs with a TF reporter gene carrying RFP, FLuc, and HSVttk driven by the ubiquitin promoter ( Figure 3A Figure 8C-D) .
Transplantation of ciPSC-ECs for murine myocardial injury model-Previous studies have demonstrated potential of iPSCand ESC derived endothelial cells to improve systolic function following myocardial infarction (MI) through revascularization (15, 16) . Hence we next delivered ciPSC-ECs stably transduced with TF reporter gene into the border zone of infarcted murine hearts. Cardiac engraftment of ciPSC-ECs was monitored noninvasively by BLI for 42 days after cell delivery. Engraftment of ciPSC-ECs was still detectable at 42 days after infarction ( Figure  5A ). Measurement of systolic function by echocardiography revealed improvement in cardiac contractility for animals receiving ciPSC-ECs as compared to animals receiving PBS at days 14 and 28 post MI. However, as in the murine hindlimb model, BLI demonstrated progressive death of donor cells following transplantation into the ischemic heart. Hence significant differences in systolic function between the two groups of animals was not observed at week 6 ( Figure 5B-C) . Histologic confirmation of ciPSC-ECs in the heart was performed using RFP immunofluorescence at day 42 following cell delivery ( Figure 5D ).
Discussion
Previous studies have shown that iPSCs can be derived from small animals such as mice and rats, demonstrating proof of principle for the therapeutic potential of pluripotent stem cell based regenerative therapies (21,22). However, these models have several limitations for extrapolation to human patients due to differences in animal physiology and size.
Development of large animal models is likely necessary for the creation of clinical criteria for iPSC-based human trials in the future. Unfortunately, efforts to establish allogeneic or autologous cell transplant models in large animals have been hampered by difficulty in isolation of stable ESC lines from farm animal species and inability to optimize cell culture conditions (23). The reasons for these reported difficulties in derivation of ESCs from large animals are not clear, but likely stem from the inability to isolate cells from the inner cell mass at the appropriate stage of embryonic development (23). Thus, the generation of stable iPSC lines from somatic tissue of large animals is a novel approach by which pluripotent stem cell studies may be established.
Several studies have demonstrated the feasibility of deriving iPSCs from larger animals, including pigs and monkeys (10, 24) . More recently, the derivation of ciPSCs from canine embryonic fibroblasts and testicular tissue has been described (25,26). However, the ciPSCs derived in these preliminary studies were not shown capable of teratoma formation, nor were compared to cESCs in terms of comprehensive analysis for markers of pluripotency. Derivation of ciPSCs that comprehensively resemble cESCs is thus still required.
Generation and maintenance of ciPSCs had several noticeable differences between that of murine and human iPSCs. First, both murine and human somatic cells have been shown to be capable of induction to a pluripotent state using feeder free systems (11) . By comparison, in the generation of ciPSCs, we were unable to propagate undifferentiated cells without a feeder layer of mouse embryonic fibroblasts (MEFs). Withdrawal of MEFs resulted in cell differentiation and loss of colony morphology. Second, both the growth factors LIF and bFGF were necessary for the derivation and maintenance of ciPSCs. This stands in contrast to murine ESCs and iPSCs, which require LIF only (27), and human ESCs and iPSCs, which require bFGF only (23). Without the addition of both LIF and bFGF, ciPSCs lost ESC-like colony morphology as well as expression of Oct-4 and TRA-1-60. Our culture system for ciPSCs may provide additional clues to help establishing other large animal ESC lines like by guest on November 17, 2017 http://www.jbc.org/ Downloaded from pig and sheep for which culture conditions have yet to be determined. Unlike the pig and sheep for which ESC lines are not available, isolation and culture of cESCs has been documented (7-9), thus allowing us to verify pluripotency and self-renewal properties of ciPSCs derived in this study.
In summary, we have successfully generated 12 ciPSC lines from 3 adult dogs. Importantly, we have used a non-invasive multi-modality imaging approach to monitor autologous iPSC transplantation in a large animal model of cardiac delivery. Both the PET reporter gene and the MR iron oxide labeling techniques we employed allow for accurate localization of cells and are directly applicable to human patients (28). Furthermore, we have generated functional endothelial cells from ciPSCs and demonstrated the therapeutic potential of these cells in murine models of hindlimb ischemia and myocardial infarction. Validating pre-clinical iPSC imaging in large animal models can be an arduous process and will be different for every cell type and targeted tissue. Undoubtedly, further endeavors will be needed to further optimize both the imaging protocols and iPSC biology synergistically to allow successful translation of pluripotent stem cell therapies to patients in the future.
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Li, Z., Hu, S., Ghosh, Z., Han, Z., and Wu, J. C. The activities were 0.0008±0.0003 (1x10 6 ), 0.0210±0.0010 (2x10 6 ), 0.0910±0.0240 (5x10 6 ), and 0.1860±0.0670 %ID/g (1x10 7 ). (D) 1x10 6 , 2x10 6 , 5x10 6 , and 10x10 6 ciPSCs stably expressing the TF reporter gene were injected into the subcutaneous flanks of mice. In vivo imaging by microPET was performed 60 minutes later. The activities were 0.0208±0.0033 (1x10 6 ), 0.1830±0.0510 (2x10 6 ), 0.2910±0.1160 (5x10 6 ), and 0.3770±0.0880 %ID/g (10x10 6 ). The minimal detectable number of ciPSCs was ~1x10 6 . and Tuj-1 (Covance, Princeton, NJ) were used in the staining (Supplemental Table 1 total iron content of 11.2 mg/ml. We prepared preservative-free protamine sulfate (American Pharmaceuticals Partner Inc., Schaumburg, IL; http://www.appdrugs.com/) with a concentration of 10 mg/ ml using a fresh stock solution of 1 mg/ml and distilled water. SPIO at a concentration of 100 µg/ml was placed into a mixing tube containing serum-free culture medium. We added protamine sulfate (12 µg/ml) and mixed the entire suspension for 5-10 minutes. We added the final FE-Pro suspension to the existing medium and incubated overnight. The final concentrations of Feridex IV and protamine sulfate were 50 and 6 µg/ml of medium, respectively. After overnight incubation, the ciPSCs were washed twice with PBS and harvested by treatment with collagenase IV and trypsin, respectively. Ex vivo imaging of dog heart by microPET. Following PET-CT imaging, animals were sacrificed by intravenous administration of saturated potassium chloride. Hearts were explanted and sectioned in a short-axis plane for ex-vivo imaging by microPET. A 4 minute static image was acquired for each section after which the hearts were fixed for histology.
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Histology of dog heart. Animal hearts were excised, rinsed, fixed in 10% neutral buffered formalin overnight, and sectioned in transverse slices. Transverse slices from the level of injection were verified by gross examination, and H&E staining was performed by means of paraffin embedding.
Differentiation of ciPSCs into canine endothelial cells (ciPSC-ECs). Generation of ciPSC-
ECs was based on previous endothelial cell differentiation protocols using human ESCs and iPSCs (5) . Briefly, ciPSCs were cultured in ultra low attachment dishes using EB differentiation Delivery of ciPSC-ECs in a murine model of hindlimb ischemia. SCID Beige mice (Charles Rivers Laboratories, MA) were anesthetized with isoflurane (2-3%) after which unilateral hindlimb ischemia was induced by ligating the femoral artery. Briefly, skin on the right leg of the mouse was dissected from the knee towards the medial thigh. After separation of the femoral artery and vein, a segment of the femoral artery was tied with a 7-0 suture and subsequently transected with spring scissors (6, 7) . To test the therapeutic potential of ciPSCECs, 1x10 6 cells stably expressing Fluc-RFP-HSVttk were delivered by intra-muscular injection into the region of ischemia (n=5). Control animals received PBS (n=5).
Laser Doppler of hindlimb perfusion. Blood perfusion of ligated and control hindlimbs was assessed using a PeriScan PIM3 laser Doppler system (Perimed AB, Sweden) as previously described (6) . Animals were placed on a 37°C heatpad, and hindlimb blood flow was measured on days 0, 7, and 14. Perfusion was quantified as mean pixel value within the entire hindlimb and the relative changes in hindlimb blood flow were expressed as the pixel ratio of the ischemic leg over the nonischemic leg. 
